Sign In
Buy LGND
$287.54
-8.75 (-2.95%)
At Close: Jul 31, 2026
Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND
03:47am, Tuesday, 28'th Jul 2026
Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the Securiti
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
07:00am, Thursday, 23'rd Jul 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 202
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks
XOMA Royalty Announces Closing of Its Acquisition by Ligand
09:00am, Tuesday, 14'th Jul 2026
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisitio
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
09:00am, Tuesday, 14'th Jul 2026
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, cre
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
10:44pm, Sunday, 12'th Jul 2026
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: C
Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
09:40pm, Tuesday, 30'th Jun 2026
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancement
Ligand Announces Closing of Convertible Senior Notes Offering
04:01pm, Thursday, 25'th Jun 2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
04:00am, Tuesday, 23'rd Jun 2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
07:00am, Monday, 22'nd Jun 2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offs
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
07:00am, Sunday, 14'th Jun 2026
Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.
Ligand Announces 2026 Investor Day in New York City
07:00am, Wednesday, 10'th Jun 2026
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 1
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
08:28am, Sunday, 07'th Jun 2026
5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Co
Ligand to Participate in June Investor Conferences
04:01pm, Wednesday, 27'th May 2026
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
Saying Goodbye To The XOMA Royalty PFDs
08:00am, Monday, 25'th May 2026
Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or
